U.S. stock market midday update: Regencell Bioscience up 7.74%

U.S. Stock Market Midday Update Regencell Bioscience rose 7.74%. Based on recent important news: On August 25, Opera launched a new browser product, Opera Neon, which has a wide global user base, driving the company's stock price up. Opera's innovative technology and market expansion have enhanced investor confidence, leading to a 7.74% increase in stock price. On August 25, Kunlun Wanwei made significant progress in the application of AI technology, enhancing its influence in domestic and international markets, becoming a benchmark enterprise in the AI field, resulting in a rise in stock price. On August 25, Dongfang Zhenxuan announced its annual financial report, with significant declines in revenue and profit, causing its stock price to drop by 14%, affecting market sentiment. Stocks with High Trading Volume in the Industry Eli Lilly rose 3.26%, with increased trading volume. Based on recent important news: On August 26, Eli Lilly announced significant results from its oral weight loss drug orforglipron in Phase III trials, leading to a 3.2% increase in stock price. On August 26, Eli Lilly reported that its GLP-1 drug achieved an average weight loss of 10.5% over 72 weeks, boosting its stock price. On August 26, Eli Lilly plans to submit a market application for orforglipron to the FDA, with a positive market reaction. Novo Nordisk fell 2.95%, with increased trading volume. Based on recent important news: On August 25, Novo Nordisk announced a 50% price reduction for Wegovy, influenced by pressure from Trump, leading to a 2.95% drop in stock price. On August 26, the FDA found significant quality control issues at Novo Nordisk's Indiana plant, including foreign contamination, further undermining market confidence. On August 24, Rosen Law Firm reminded investors to seek legal counsel before the deadline for securities class action lawsuits, increasing uncertainty among investors. Pfizer fell 0.22%, with increased trading volume. Based on recent important news: On August 26, U.S. President Trump announced a 1400% to 1500% reduction in drug prices and plans to impose higher tariffs on imported drugs, causing Pfizer's stock price to decline. On August 26, Pfizer faces legal risks, having historically been fined $2.3 billion for fraudulent marketing, raising investor concerns. On August 26, analysts hold a wait-and-see attitude towards Pfizer, believing that five other stocks have greater investment value, affecting market confidence. Stocks with High Market Capitalization in the Industry Johnson & Johnson fell 0.54%, with increased trading volume. Based on recent important news: On August 25, Johnson & Johnson CEO Joaquin Duato sold company common stock, raising market concerns about internal confidence, leading to a drop in stock price. On August 22, Johnson & Johnson's new indication application for Niraparib and Abiraterone tablets was accepted, failing to boost market confidence On August 24th, analysts believe that Johnson & Johnson is not on the current best investment list, affecting investor sentiment